B cell depletion therapy for new-onset opsoclonus-myoclonus

Movement Disorders

Volumn 25, Issue 2, 2010, Pages 238-242

  Pranzatelli, Michael R ^a   Tate, Elizabeth D ^a   Swan, Jennifer A ^a   Travelstead, Anna L ^a   Colliver, Jerry A ^a   Verhulst, Steven J ^a   Crosley, Carl J ^b   Graf, William D ^c   Joseph, Suja A ^d   Kelfer, Howard M ^e   Raju, G Praveen ^f  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e Cook Children's Medical Center ^*  (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

ACTH; Anti B cell agent; Dancing eyes; Kinsbourne syndrome; Neuroblastoma; Paraneoplastic syndrome; Rituximab

Indexed keywords

CHIMERIC ANTIBODY; CORTICOTROPIN[1-39]; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; PENTAMIDINE; RITUXIMAB;

ANTIBODY TITER; ARTICLE; ATAXIA; B LYMPHOCYTE; BACTERIAL INFECTION; CELL EXPANSION; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CUSHINGOID SYNDROME; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FACE MALFORMATION; FACIAL PUFFINESS; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALAISE; MALE; MONITORING; NAUSEA; OPSOCLONUS MYOCLONUS SYNDROME; PRIORITY JOURNAL; RELAPSE; REMISSION; SAFETY; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ADRENOCORTICOTROPIC HORMONE; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATAXIA; B-LYMPHOCYTES; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INFANT; LYMPHOCYTE DEPLETION; MALE; MYOCLONUS; OPSOCLONUS-MYOCLONUS SYNDROME; TREATMENT OUTCOME;

EID: 77649134992     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22941     Document Type: Article

References (16)

1. Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Dis 2004;19:770-777.
2. Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005;22:8-19.
3. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;4:557-567.
4. Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004;62:1526-1532.
5. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006;28:585-593.
6. Pranzatelli MR, Tate ED, Travelstead AL, Verhulst SJ. CSF B cell over-expansion in paraneoplastic opsoclonus-myoclonus: effect of rituximab, an anti-B cell monoclonal antibody. Neurology 2003;60(suppl 1):A395.
7. Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus. Pediatrics 2005;115:e115-e119.
8. Tersak JM, Safier RA, Schor NF. Rituximab (anti-CD20) in the treatment of refractory neuroblastoma-associated opsoclonusmyoclonus syndrome. Ann Neurol 2005;58(suppl 9):S111.
9. Bell J, Moran C, Blatt J. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 2008;50:370-371.
10. Leen WG, Weemaes CM, Verbeek MM, Willemsen MA, Rotteveel JJ. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol 2008;39:213-217.
11. Corapcioglu F, Mutlu H, Kara B, et al. Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma. Pediatr Hematol Oncol 2008; 25:756-761.
12. Pranzatelli MR. The immunopharmacology of the opsoclonusmyoclonus syndrome. Clin Neuropharmacol 1996;19:1-47.
13. Guilino LB, Bussel JB, Neufeld EJ. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr 2007;205:338-344.
14. Pranzatelli MR, Huang Y, Tate E, et al. Monoaminergic effects of high dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Mov Disord 1998;13:522-528.
15. Pranzatelli MR, Tate ED, Galvan I, Wheeler A. Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus. Clin Neuropharmacol 2001;24:352-357.
16. de Graaf M, de Beukelaar J, Bergsma J, et al. B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. J Neuroimmunol 2008;195:164-170.